Adage Capital Partners Gp, L.L.C. I Teos Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$10.95 - $14.6 $219,000 - $292,000	20,000 New	20,000 $219,000
Q2 2022 Aug 15, 2022	SELL	$16.57 - $35.1 $1.74 Million - $3.69 Million	-105,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$31.92 - $47.45 $2.07 Million - $3.08 Million	-65,000 Reduced 38.24%	105,000 $3.38 Million
Q4 2021 Feb 14, 2022	BUY	$26.23 - $47.86 $1.97 Million - $3.59 Million	75,000 Added 78.95%	170,000 $7.92 Million
Q3 2021 Nov 15, 2021	BUY	$23.91 - $29.58 $911,138 - $1.13 Million	38,107 Added 66.98%	95,000 $2.57 Million
Q2 2021 Aug 16, 2021	SELL	$17.9 - $36.1 $21.5 Million - $43.3 Million	-1,200,000 Reduced 95.47%	56,893 $1.46 Million
Q1 2021 May 17, 2021	BUY	$30.86 - $44.2 $28.7 Million - $41.1 Million	930,036 Added 284.54%	1,256,893 $43 Million
Q4 2020 Feb 16, 2021	BUY	$21.59 - $33.95 $7.06 Million - $11.1 Million	326,857 New	326,857 $11.1 Million

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.